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An HPLC-peroxyoxalate chemiluminescence (PO-CL) method for simultaneous 
determination of methylphenidate (MPH) and ritalinic acid (RA) was developed. 
Furthermore, the proposed method was applied to monitor MPH and RA after an 
administration of MPH to rat. The deproteinized plasma spiked with 
1-(3-trifluoromethylphenyl)piperazine (IS) was dried up and labeled with 
4-(N,N-dimethylaminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole (DBD-F). The labeled 
sample was cleaned-up with two kinds of solid-phase extraction cartridges, and the 
DBD-labels were separated on an ODS column with gradient elution using a mixture of 
CH3CN and imidazole-HNO3 buffer. The separation of MPH and RA can be achieved 
within 33 min. The LODs of MPH and RA at signal-to-noise ratio of 3 were 2.2 and 0.4 
ng/mL, respectively. Moreover, monitoring of MPH and RA after MPH administration 
(10 mg/kg) to rat could be performed. The concentration of RA at 480 min after 
administration was 8 times higher than that of MPH. 
The proposed HPLC-PO-CL method was useful for determination of MPH and RA 
in rat plasma and was successfully applied to monitor these substances after MPH 
administration. (172 words) 
 
 






Methylphenidate (MPH), a phenethylamine derivative, is a well-known medicament 
for attention-deficit hyperactivity disorder and narcolepsy [1]. It is known that there is 
marked individual variability in the dose-response relationship for MPH, and therefore 
dosage must be titrated for optimal effect and avoidance of toxicity in each patient [2,3]. 
However, it is unclear whether this variability is predominantly pharmacokinetic or 
pharmacodynamic. MPH is reported to be absorbed rapidly and completely from the 
intestine after oral administration and hydrolyzed at the methyl ester moiety to its main 
metabolite, ritalinic acid (RA) [4]. And in human carboxylesterase contributes to 
hydrolyze MPH stereo-selectively to RA [5]. In order to fully assess the processes 
associated with metabolic clearance, simultaneous determination of MPH and RA might 
be needed, though RA is a major inactive metabolite.  
Due to its similar pharmacological effect of amphetamine, MPH has been illicitly 
abused [2,6]. Recent fatalities due to the abuse of MPH have been reported [6]. To 
distinguish MPH abuse from external contamination of sample by MPH, identification 
of MPH and its metabolite in the sample was simultaneously required. Therefore, a 
simple and reliable analytical method to determine MPH and RA is in requisite, due to 
their clinical and forensic interests described above. However, only a few methods for 
simultaneous determination of MPH and RA in biological samples have been reported 
[7-9]. Chromatographic behavior between MPH and RA is different, because polarity of 
RA is higher than that of MPH. This is one of reasons for difficulty on simultaneous 
determination of MPH and RA. 
Several analytical methods have been reported for the determination of MPH and/or 
RA in biological matrices. Gas chromatography-mass spectrometry [10,11], HPLC-UV 
3 
 
[12-14], -fluorescence (-FL) detections [15], liquid chromatography (LC-MS) 
[5,7-9,16,17] and LC-tandem mass spectrometry (LC-MS/MS) [2,18,19] methods were 
widely used. Quite recently, MS detection for very low-level quantification of MPH in 
biological samples has been frequently used. However, the use of MS detector, which is 
large and expensive equipment, is restricted. Simultaneous determination of MPH and 
RA by FL detection with nano-g level of sensitivity has never been achieved previously. 
On the other hand, a peroxyoxalate chemiluminescence (PO-CL) method, which is a 
powerful tool to determine fluorophore, has been used to determine trace amounts of 
biologically active compounds such as drugs in biological samples due to its high 
sensitivity and selectivity [20]. Thus sensitive determination of MPH and RA might be 
achieved by an HPLC-PO-CL method combined with FL labeling technique, although 
no previous achievement has been ever reported. In our previous study, we already 
developed a sensitive HPLC-PO-CL method for determination of MDMA-related 
compounds [21].  
In this study, an HPLC- PO-CL method for simultaneous determination of MPH and 
RA labeled with 4-(N,N-dimethylaminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole 
(DBD-F) was developed. To clean-up labeled sample, two types of solid-phase 
extraction (SPE) cartridges were used. Furthermore, the proposed method was applied 




Materials and methods 
Chemicals 
   MPH was purchased from Sigma Chemical Co. (MO, USA). RA and 
1-(3-trifluoromethylphenyl)piperazine (TFMPP), used as an internal standard (IS), were 
gifted from National Institute of Health Sciences (Tokyo, Japan). DBD-F and imidazole 
were obtained from Tokyo Kasei Kogyo Co. (Tokyo). 
Bis(2,4,5-trichloro-6-carbopentoxyphenyl)oxalate (CPPO) was kindly gifted from 
Lumica Co. (Fukuoka, Japan). Other reagents used were of analytical reagent grade. 
Water was purified by passing through a Pure Line WL21P system (Yamato Scientific 
Co., Tokyo, Japan). A stock standard solution (1 mg/mL) of MPH and RA were 
prepared by dissolving in MeOH and stored at -30C until analysis. 
 
Pretreatment of plasma sample 
Fifty-L of plasma spiked with 10 L of IS in CH3CN were deprotenized with 500 
L of CH3CN. After centrifugation (3500g) at 20℃  for 10 min, the resulted 
supernatant was dried-up and the residue was applied to labeling reaction with DBD-F.  
Each 50-L of borate buffer (100 mM, pH 8.5) and 120 mM DBD-F in CH3CN 
were spiked to the residue, and heated at 80℃ for 30 min in the dark (Fig. 1). The 
reaction mixture was cooled in ice-water to stop the reaction.  
The reaction mixture with DBD-F was applied to SPE cartridges to eliminate the 
excess reagent and interfering materials for detection of MPH- and RA-DBD. 
Cleaned-up with 2 kinds of SPE cartridges, which are Varian Bond Elut® C18 for MPH 
and IS, and Waters Oasis® MAX for RA were used. Both cartridges were conditioned 




C18 and washed with 3 mL of CH3CN/H2O (=40:60, v/v). Then the MPH-DBD was 
obtained by eluting with 500 L of MeOH. The washing solution obtained from Varian 
Bond Elut® C18 was applied to Waters Oasis® MAX. The Waters Oasis® MAX was 
washed with 2 mL of MeOH and eluted with 500 L of 2% acetic acid in MeOH for 
RA-DBD. Then both eluates were combined and dried-up under N2 gas. Finally, residue 
was reconstituted with 100 L of CH3CN and applied to HPLC analysis. 
Fig. 1 
HPLC conditions 
The HPLC system for separation of MPH- and RA-DBD labels is shown in Fig. 2. It 
was consisted of three chromatographic pumps to flow mobile phase (2×LC-20AD, 
Shimadzu, Kyoto, Japan) and CL reagent (LC-10ADVP, Shimadzu), a system controller 
(SCL-10 ADVP, Shimadzu), a 7125 injector with a 20-L of sample loop (Rheodyne, 
CA, USA), a Daisopak-SP-ODS-BP column (250×2.0 mm, i.d., 5 m, Daiso, Osaka, 
Japan), a UNI-1 noise cleaner (Union, Gunma, Japan) which smoothes the baseline, a 
CL2027 Plus chemiluminescence detector (Jasco, Tokyo) and a recorder (FBR-2, Tosoh, 
Tokyo). The solutions, CH3CN (MP 1) and 10 mM imidazole-HNO3 buffer (pH 7.0, MP 
2) were used as mobile phases and total flow rate was set at 0.3 mL/min. The gradient 
program to separate DBD labels was set as follows; the ratio of MP 1 was initialized at 
10% (0 to 10.0 min), linearly ramped to 60% (10.1 to 14.0 min), preserved 60% (14.1 to 
35.0 min), changed to 90% (35.1 to 45.0 min) for washing and then 10% (45.1 to 55.0 
min) for equilibration of the analytical column. A mixture of 4 mM CPPO and 37.5 mM 





Validation of the method 
   The standard of MPH and RA solutions spiked plasma were independently prepared 
adequate times in validation study. For determination of MPH and RA, calibration 
curves using rat plasma spiked with known concentration of standards prepared 
independently three times were prepared by the internal standard method. The IS 
solution containing standards were spiked to prepare the calibration curves. The 
calibration equations and correlation coefficients using the model of least squares were 
calculated by the software JMP® 8.0.2 (SAS Institute Japan, Tokyo). Plasma samples 
spiked with MPH ranging from 10 to 1000 ng/mL plasma and RA ranging from 100 to 
10000 ng/mL plasma were prepared. The limit of detection (LOD) and quantification 
(LOQ) were defined as a concentration given signal-to-noise (S/N) ratio of 3 and 10. 
Recovery of the proposed method was expressed as the peak height ratio between 
standards spiked in plasma with SPE step and standards without clean-up with SPE. 
Accuracy and precision for inter-day and intra-day assay were evaluated by using 
plasma samples spiked with 10, 50 and 500 ng/mL of MPH, and 100, 500 and 5000 
ng/mL of RA, respectively. Data was expressed as mean±SD (n=6).  
 
Pharmacokinetic study of MPH and RA 
Wistar male rats (n=3, 280-300 g, Otsubo experimental animals, Nagasaki, Japan) were 
used. Rats were anesthetized with ethyl carbamate (1.5 g/kg) before cannulation. From 
cannulated femoral artery, blood samples were collected into the test tube containing 
EDTA-2Na for preparation of plasma. Blood sampling was performed at 0, 15, 30, 45, 
60, 90, 120, 180, 240, 300, 360, 420 and 480 min after administration of MPH (10 
mg/kg, i.p.). After centrifugation (1000g) at 4˚C for 10 min, plasma was kept at -30˚C 
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until analysis. The pharmacokinetic parameters such as elimination rate constant (K), 
elimination half-life (T1/2), distribution volume (V) and clearance (CLR) of MPH were 
manually calculated with one-compartment model analysis. The area under the curve 
(AUC) of MPH and RA was manually calculated by trapezoidal method. The data was 
presented as mean±SD (n=3). 
   This experiment was performed with an approval of Nagasaki University Animal 




Results and discussion 
Optimization of pretreatment conditions of sample 
   Labeling conditions such as DBD-F and borate buffer (pH 8.5) concentrations and 
reaction time were examined. 1.0 g/mL of MPH standard solution was used and its 
chemiluminescence intensity (CLI) and decomposition ratio to RA were evaluated. At 
first, the effects of DBD-F concentration (20-320 mM) on the CLI were examined. 
DIB-MPH gave maximum CLI with 120 mM and decomposition ratio of MPH 
decreased with increase of DBD-F concentration, thus the following experiments were 
done using 120 mM DBD-F. Next, concentration of borate buffer ranging from 25 to 
150 mM was examined, and maximum constant CLI was achieved using more than 75 
mM of borate buffer with low decomposition ratio of MPH, thus 100 mM was selected. 
Finally, reaction time at room temperature was studied in the range of 10-60 min. 
Maximum CLI was given by 30 min of reaction time, and longer reaction time than 30 
min brought decomposition of MPH. The following experiments were done at room 
temperature for 30 min. In our preliminary study, acceleration of decomposition of 
MPH by heating was found (data is not shown), so labeling reaction at room 
temperature was demonstrated.  
   Deprotenization of plasma sample with CH3CN was performed before labeling. It 
improved the recovery of MPH and FA. 
   To remove excess DBD-F, clean-up with SPE cartridge was performed. Varian Bond 
Elut® C18 could retain MPH- and IS-DBD labels, although RA-DBD was eluted with 
washing solution. On the other hand, the Waters Oasis® MAX, a mixed-mode sorbent 
consisting of a strong anion exchanger and a non-polar 
N-vinylpyrrolidone/divinylbenzene polymer, well-retained RA-DBD, however, the 
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recoveries of MPH- and IS-DBD labels were not satisfactory. So the reaction mixture 
with DBD-F was applied to Varian Bond Elut® C18 at first to recover the MPH- and 
IS-DBD labels. Then the washing solution of the Varian Bond Elut® C18 containing 
RA-DBD was applied to the Waters Oasis® MAX to recover the RA-DBD. Then both 
eluates were collected and reconstituted with CH3CN after drying-up under N2 gas. The 
recoveries of MPH- and RA-DBD were 50.0% and 43.8%, respectively. The recoveries 
of MPH and RA in previous reports demonstrated simultaneous determination these 
compounds were not mentioned clearly [7, 9]. And moderate recoveries (75% for MPH 
and 60% for RA) were obtained by LC-MS with SPE (Oasis HLB cartridge, Waters) [8]. 
To improve recovery, further examination with other SPE cartridges should be needed.  
 
HPLC and CL detection conditions  
  At first, the isocratic separation of MPH- and RA-DBD was attempted. Since 
chromatographic behavior of both labels on reversed phase column 
(Daisopak-SP-ODS-BP column) was remarkably different, their satisfactory separation 
from interfering peaks with acceptable analysis time could not be obtained. Therefore 
gradient elution with CH3CN (MP 1) and 10 mM imidazole-HNO3 buffer (pH 7.0, MP 
2) was performed. The retention times of MPH-, RA and IS-DBD labels were 29.5, 13.0 
and 33.0 min, respectively. Total run time including washing and equilibration steps 
after eluting of IS-DBD label was 55 min. 
   Optimization of PO-CL detection conditions such as concentrations of CPPO and 
H2O2 and flow rate of CL reagent was demonstrated. A mixture of CPPO and H2O2 in 
CH3CN was used as a post column CL reagent. One g/mL of MPH standard solution 
was used and its chemiluminescence intensity (CLI) was evaluated. CPPO ranging from 
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1 to 8 mM was used. More than 2 mM of CPPO gave maximum and constant CLI of 
MPH. Next, H2O2 concentration in the range of 25-100 mM (25.0, 37.5, 50.0, 75.0 and 
100.0 mM) was examined, maximum CLI of MPH was obtained at 37.5 mM. Effect of 
flow rate of CL reagent on CLI of MPH was examined (at 0.30, 0.38, 0.45, 0.60 and 0.9 
mL/min). More than 0.4 mL/min of flow rate gave the maximum and constant CLI of 
MPH. The following experiments were done by using CL reagent containing 4 mM of 
CPPO and 37.5 mM of H2O2 flowed at 0.45 mL/min. 
 
Validation of the proposed method 
Calibration curves of MPH and RA obtained with spiked plasma were linear with 
r-values greater than 0.998 in the ranges of 10-1000 ng/mL and 100-10000 ng/mL. 
Since concentration range of RA in plasma sample after administration might be 10 
times higher than that of MPH, high concentrations for preparation of RA calibration 
curve were used. The LODs of MPH and RA at S/N ratio of 3 were 2.2 ng/mL (93.2 
fmol on column) and 0.4 ng/mL (20.2 fmol on column), respectively, and the LOQs at 
S/N ratio of 10 were 7.3 ng/mL (MPH) and 1.3 ng/mL (RA).  
   Accuracy, intra- and inter-day precisions of the proposed method were evaluated 
by analyzing plasma spiked with known concentrations of MPH (10, 50 and 500 
ng/mL) and RA (100, 500 and 5000 ng/mL) as shown in Table 1. Accuracy in the range 
of 91.6±8.9%-108.9±2.4% was obtained. The intra-day RSDs for MPH and RA were 
9.7 (10 ng/mL), 2.2 (50 ng/mL) and 3.6 % (500 ng/mL), and 6.2 (100 ng/mL), 3.1 (500 
ng/mL) and 2.7 % (5000 ng/mL), respectively. Inter-day precision (RSDs) of 9.3 (10 
ng/mL), 5.0 (50 ng/mL) and 8.7 % (500 ng/mL) for MPH were obtained, while those for 
RA were 7.0 (100 ng/mL), 6.1 (500 ng/mL) and 6.7 % (5000 ng/mL). By our method, 
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decomposition of MPH to RA was not found. Because peak of RA did not appear when 
the plasma spiked with MPH was analyzed. 
The sensitivity and plasma volume required for measurement of the proposed 
method and conventional methods were summarized in Table 2. Plasma volume 
required for measurement in our method was comparable to those of the conventional 
methods [7-9], though our method was less sensitive. The method reporting completed 
simultaneous determination of MPH and RA are rare. One of the reasons might be 
remarkable difference of chromatographic behavior of these compounds on reversed 
phase chromatography. To our knowledge, only LC-MS methods to determine MPH and 
RA simultaneously in plasma could be achieved [7-9]. The MS detection having 
excellent selectivity negotiates this difference on chromatographic behavior. In this 
study, the combination of fluorescence labeling of substances, clean-up step and 
gradient elution overcame it.  
Table 1 
Table 2 
Pharmacokinetic study of MPH and RA 
Furthermore, the proposed method was applied to monitor of MPH and RA 
concentration after MPH administration to rat. Chromatograms of rat plasma spiked 
with IS (A) and that obtained at 45 min after i.p. administration of MPH (10 mg/kg) (B) 
are shown in Fig. 2. An asterisk indicates that the detector sensitivity is set 5 times 
higher at that point of the analysis due to the higher concentration of RA compared with 
that of MPH. The concentrations of MPH and RA in the chromatogram corresponded to 
482.5 and 238.8 ng/mL, respectively. And the concentration–time profiles of MPH and 
RA are shown in Fig. 3. The concentrations of MPH and RA in plasma were in the 
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range of 16.5-482.5 ng/mL and 219.4-745.9 ng/mL, respectively. The SD of RA 
concentrations were varied due to the variance of the time to reach plateau 
concentration of RA. 
By using the proposed method MPH could be monitored after 480 min of 
administration. MPH was hydrolyzed to RA rapidly and this fact agrees with that in 
previous report [3]. The concentration of RA at 480 min after administration was kept 
high levels and 8 times higher than that of MPH. Pharmacokinetic parameters of MPH 
and RA was calculated and is summarized in Table 3. The K (0.0046±0.0027 min-1) and 
CLR (0.025±0.009 L/min) of MPH obtained in this study were similar to those in 
previous report [3]. Kennerly et al., reported MPH is also metabolized to p-hydroxy 
methylphenidate in rat, but its concentration was lower than that of MPH [4]. In our 
study, no peak corresponding to p-hydroxy methylphenidate was found on the 







The proposed HPLC-PO-CL method was useful for simultaneous determination 
of MPH and RA in rat plasma. The reason of difficulties of simultaneous determination 
of MPH and RA might be the remarkable difference of chromatographic behavior of 
both compounds. Using fluorescence labeling, two types of SPE cartridges for clean-up 
step, gradient elution, and PO-CL detection, sensitive and selective determination of 
these compounds was achieved. Validation parameters of MPH and RA in plasma 
obtained were acceptable. Furthermore, this method could be successfully applied to 
monitor these substances after MPH administration to rat. Due to these results, the 
proposed method was apparently simple and reliable, and suitable to apply over 
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Fig. 3 Chromatograms of rat plasma spiked with IS (A) and that obtained at 45 min 
after i.p. administration of MPH (10 mg/kg) (B). 





Fig. 4 Concentration-time profiles of MPH and RA in plasma after administration of 
MPH to rat. 
Data was presented as mean±SD (n=3). 
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Precision % (RSD) 
Intra-day Inter-day 
MPH 10 91.6±8.9 9.7 9.3 
 50 108.9±2.4 2.2 5.0 
 500 99.4±3.6 3.6 8.7 
RA 100 93.6±5.8 6.2 7.0 
 500 107.6±3.3 3.1 6.1 
 5000 95.0±2.6 2.7 6.7 








Method LOD  LOQ Plasma 
volume, L 
Ref. 
MPH, RA HPLC-PO-CL 
Labeled with DBD-F 
MPH: 2.2 ng/mL 
RA: 0.4 ng/mL 
(S/N=3) 
MPH: 7.3 ng/mL 





10 ng/mL (S/N=2)  300 13 
MPH HPLC-FL (ex=330, 
em=460 nm) 
Labeled with DIB-Cl1 




MPH, RA LC-MS MPH and RA: 0.31 
ng/mL (3 × SD of 
noise level) 
MPH and RA: 1.0 
ng/mL (10×SD of 
noise level  
RSD<20%) 
100 7 
MPH, RA LC-MS MPH and RA: 0.075 
ng/mL (S/N=3) 
MPH and RA: 0.25 
ng/mL (S/N=10) 
100 8 
MPH, RA LC-MS  MPH: 0.1 ng/mL 
RA: 0.5 ng/mL 
(RSD=20%) 
25 9 
1 DIB-Cl: 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride. 
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Table 3 Pharmacokinetic parameters of MPH and RA. 
Pharmacokinetic parameter Mean±SD (n=3) 
[MPH]  
K, min-1 0.0046±0.0027 
T1/2, min 200±136 
V, L 6.1±2.2 
CLR, L/min 0.025±0.009 
AUC, mg·min/L 98±22 
[RA]  
AUC, mg·min/L 232±40 
Data was presented as mean±SD (n=3). 
Abbreviations: K, elimination rate constant; T1/2, half-life time; V, distribution volume; 
CLR, clearance; AUC, area under the curve. 
